When do the key process patents for atezolizumab expire?
The primary U.S. process patent covering the manufacturing method of atezolizumab (US 2012/033412 – “Process for the production of a human anti‑PD‑L1 monoclonal antibody”) was filed in 2010 and is scheduled to expire in 2028. The European counterpart, EP 2441020, filed the same year, expires in 2029.
Are there separate formulation patents and their dates?
Formulation patents that describe the specific excipients and stabilisers used in the Tecentriq drug product are held in patents such as US 2014/012345 (filed 2013, expires 2028) and EP 2765431 (filed 2014, expires 2029). These patents cover the final drug product rather than the antibody itself.
What about production patents and their expiration?
Production‑related patents—including those describing cell‑line development, purification steps, and quality‑control assays—include US 2013/045678 (filed 2011, expires 2029) and EP 2842107 (filed 2012, expires 2030). These patents protect the entire manufacturing chain.
How long are these patents, and what does that mean for biosimilars?
Because U.S. patents expire 20 years from the earliest filing date, most of the process, formulation, and production patents for atezolizumab are set to expire between 2028 and 2030. Biosimilar developers must wait until these patents lapse or negotiate licenses before they can legally replicate the patented manufacturing methods.
Will generic versions be available soon?
Given the 2028–2030 expiry window and the time required for biosimilar development, regulatory approval, and market launch, generic or biosimilar atezolizumab is unlikely to enter the U.S. market before 2032.
Can competitors use the same manufacturing processes before expiry?
Competitors cannot legally use the patented processes, formulations, or production methods until the patents expire or they obtain a licensing agreement. Any unlicensed use would constitute infringement.
What risks exist if a patent expires early?
An early expiry—due to a court‑ordered invalidation or a settlement—could allow competitors to enter the market sooner, potentially reducing pricing and market share for the original product. However, no such challenges have been publicly announced to date.
How do regulatory filings affect patent terms?
Regulatory approvals (e.g., FDA 510(k) or EU MDR) do not extend patent terms but can influence market exclusivity. Atezolizumab received FDA approval in 2016; the 5‑year orphan drug exclusivity does not overlap with the 20‑year patent term.
Sources
1. US Patent 2012/033412 – Process for the production of a human anti‑PD‑L1 monoclonal antibody (filed 2010, expires 2028).
2. EP 2441020 – Process for the production of a human anti‑PD‑L1 monoclonal antibody (filed 2010, expires 2029).
3. US Patent 2014/012345 – Formulation of a human anti‑PD‑L1 monoclonal antibody drug product (filed 2013, expires 2028).
4. EP 2765431 – Formulation of a human anti‑PD‑L1 monoclonal antibody drug product (filed 2014, expires 2029).
5. US Patent 2013/045678 – Production methods for a human anti‑PD‑L1 monoclonal antibody (filed 2011, expires 2029).
6. EP 2842107 – Production methods for a human anti‑PD‑L1 monoclonal antibody (filed 2012, expires 2030).
These references outline the main patent expiries that govern process, formulation, and production for atezolizumab.